Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain

Advances in recombinant antibody technology and protein engineering have provided the opportunity to reduce antibodies to their smallest binding domain components and have concomitantly driven the requirement for devising strategies to increase serum half-life to optimise drug exposure, thereby incr...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Müller, Mischa R., Saunders, Kenneth, Grace, Christopher, Jin, Macy, Piche-Nicholas, Nicole, Steven, John, O’Dwyer, Ronan, Wu, Leeying, Khetemenee, Lam, Vugmeyster, Yulia, Hickling, Timothy P., Tchistiakova, Lioudmila, Olland, Stephane, Gill, Davinder, Jensen, Allan, Barelle, Caroline J.
Format: Artigo
Langue:Inglês
Publié: Landes Bioscience 2012
Sujets:
Report
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3502234/
https://ncbi.nlm.nih.gov/pubmed/23676205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/mabs.22242
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires